Company Encyclopedia
View More
name
Ernexa Therapeutics
ERNA.US
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc.
1.897 T
ERNA.USMarket value -Rank by Market Cap -/-

Financial Score

19/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking315/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE87.78%A
    • Profit Margin-1834100.00%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-99.83%E
    • Net Profit YoY59.16%B
    • Total Assets YoY-20.03%E
    • Net Assets YoY107.86%A
  • Cash ScoreE
    • Cash Flow Margin-0.01%D
    • OCF YoY-99.83%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreC
    • Gearing Ratio42.16%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials | ERNA Stock News

    Ernexa Therapeutics reported a 44% year-over-year decline in operating loss, reflecting strong operational execution. The company is advancing its lead program, ERNA-101, toward a Phase 1 study in platinum-resistant ovarian cancer, expected in H2 2026. Recent highlights include a manufacturing partnership and positive data presentations at major conferences. Financial results show a decrease in general and administrative expenses, contributing to improved financial performance. Ernexa focuses on innovative cell therapies for cancer and autoimmune diseases, utilizing synthetic, allogeneic induced mesenchymal stem cells.

    StockTitan·
    US
    ERNA
    -6.08%
    StockTitan·
    US
    ERNA
    -6.08%

    Ernexa Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ERNA
    -6.08%
    LB filings·
    US
    ERNA
    -6.08%

    Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform

    Access the "What This Means" segment here ...

    GlobeNewswire·
    US
    ERNA
    -6.08%
    GlobeNewswire·
    US
    ERNA
    -6.08%

    Pre-market hot trades in the US stock market: Hyperscale Data pre-market down 9.31%; Ernexa Therapeutics pre-market down 8.52%

    Hyperscale Data pre-market down 9.31%; Ernexa Therapeutics pre-market down 8.52%; VCI Global pre-market up 107.22%; Cambium Networks pre-market up 89.15%; VivoSim Labs pre-market up 84.78%

    Tracking Unusual Activity·
    US
    GPUS
    -6.04%
    US
    ERNA
    -6.08%
    Tracking Unusual Activity·
    US
    GPUS
    -6.04%
    US
    ERNA
    -6.08%

    Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer | ERNA Stock News

    Cellipont Bioservices has partnered with Ernexa Therapeutics to advance ERNA-101, a cell therapy for ovarian cancer, into clinical trials. The collaboration will focus on Engineering, Differentiation, and Production (EDP) activities to support the manufacturing process. ERNA-101 aims to activate the immune system against cancer cells and has shown promise in preclinical studies. This partnership marks a significant step in developing innovative cell therapies for advanced cancer treatment.

    StockTitan·
    US
    ERNA
    -6.08%
    StockTitan·
    US
    ERNA
    -6.08%